+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Atrial Fibrillation Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2032

  • PDF Icon

    Drug Pipelines

  • 150 Pages
  • June 2023
  • Region: Global
  • GlobalData
  • ID: 5849243
Description Jump to:
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan, Canada) and provides an Excel-based forecast model for the Atrial Fibrillation (AF) market through 2032.

In 2022, the publisher estimated that the global AF market reached $14.53 billion across the 8MM. The US makes up the majority of total global sales, contributing $10.75 billion (74%) due to the large prevalent AF population in the US, early adoption of the new oral anticoagulants (NOACs), and higher prices for AF medications in this market. The publisher anticipates that the AF market will decline at a negative compound annual growth rate (CAGR) of 1.3%, to be worth approximately $12.8 billion by 2032. The US is expected to maintain its position as the market leader in 2032, contributing 74% towards the total global sales.

The major growth drivers in the AF market during the forecast period include the following::

  • A total of five pipeline products, including four anticoagulants and one cardioversion agent, will launch during the forecast period, each of which will have a higher annual cost of therapy (ACOT) when compared with the cost of generic NOACs and the commonly used pharmacological agents, respectively
  • Factor XI (FXI)/FXIa inhibitors, including abelacimab, asundexian, and milvexian, will be welcomed by the many AF patients who are not treated with the currently available anticoagulants due to bleeding concerns
  • In the 8MM, the number of 12-month total prevalent cases of AF treated is expected to increase during the forecast period, which will drive sales
  • Continued increases in AF awareness will improve diagnosis rates

The major barriers to growth in the AF market during the forecast period include the following::

  • All four NOACs will face generic erosion as their patents expire over the forecast period
  • The AF market is crowded with inexpensive generic products for the maintenance of rate and rhythm control. The high use of these products is expected to continue throughout the forecast period, presenting a stiff barrier of entry for pipeline drugs
  • High cost of FXI/FXIa inhibitors compared to the NOAC generics will likely hinder patient uptake

Key Highlights

  • In 2022, the publisher estimated that the global AF market reached $14.53 billion across the 8MM, and anticipates that it will decline at a negative compound annual growth rate (CAGR) of 1.3%, to be worth approximately $12.8 billion by 2032
  • This decline in sales is due to the fact that novel oral anticoagulants (NOACs) will face generic erosion as their patents expire over the forecast period. In addition, the high cost of upcoming FXI/FXIa inhibitors compared to the NOAC generics will likely hinder patient uptake

Scope

  • Overview of AF, including epidemiology, symptoms, diagnosis, and disease management
  • Annualized AF therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the AF therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AF treatment. The most promising candidates in late-stage development are profiled
  • Analysis of the current and future market competition in the global AF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
  • Develop business strategies by understanding the trends shaping and driving the 8MM AF therapeutics market
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM AF therapeutics market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Atrial Fibrillation: Executive Summary
1.1 AF market will decline at a negative CAGR of 1.3%
1.2 Bayer and Bristol Myers Squibb will continue to lead the AF market over the forecast period
1.3 While outlook in AF improves, opportunities remain to improve patient outcomes
1.4 Bayer’s FXIa inhibitor asundexian will be a key driver of growth
1.5 What do physicians think?
2 Introduction
2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports
3 Disease Overview
3.1 Etiology and pathophysiology
3.2 Classification
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 8MM Forecast Methodology
4.5 Epidemiological Forecast for atrial fibrillation
4.6 Discussion
5 Disease Management
5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management
6 Competitive Assessment
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Development of anticoagulants with reduced risk of bleeding
7.3 Therapies for atrial fibrillation patients with ESRD
7.4 Safer antiarrhythmic drugs for the maintenance of sinus rhythm
7.5 Effective and rapid-acting cardioversion drugs
8 R&D Strategies
8.1 Overview
8.2 Clinical trials design
9 Pipeline Assessment
9.1 Overview
9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-making trends
12 Market Outlook
12.1 Global markets
12.2 US
12.3 5EU
12.4 Japan
12.5 Canada
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.4 Primary research - KOLs interviewed for this report
13.5 Primary research - prescriber survey
13.6 About the Authors
  • Contact the Publisher
List of Tables
Table 1: Atrial fibrillation: key metrics in the 8MM
Table 2: Common cardiac and non-cardiac causes of AF
Table 3: Classification of AF
Table 4: Risk factors and comorbidities for AF
Table 5: CHADS2 index for stroke risk assessment
Table 6: CHA2DS2-VASc index for stroke risk assessment
Table 7: Treatment guidelines for atrial fibrillation
Table 8: Atrial fibrillation market - global drivers and barriers, 2022-32
Table 9: Key events impacting sales for atrial fibrillation in the US, 2022-32
Table 10: Atrial fibrillation market - drivers and barriers in the US, 2022-32
Table 11: Key events impacting sales for atrial fibrillation in the 5EU, 2022-32
Table 12: Atrial fibrillation market - drivers and barriers in the 5EU, 2022-32
Table 13: Key events impacting sales for atrial fibrillation in Japan, 2022-32
Table 14: Atrial fibrillation market - drivers and barriers in Japan, 2022-32
Table 15: Key events impacting sales for atrial fibrillation in Canada, 2022-32
Table 16: Atrial fibrillation market - drivers and barriers in Canada, 2022-32
Table 17: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: Global sales forecast by country for atrial fibrillation in 2022 and 2032
Figure 2: Analysis of the company portfolio gap in atrial fibrillation during the forecast period
Figure 3: Competitive assessment of the pipeline anticoagulant drugs benchmarked against the current SOC
Figure 4: Competitive assessment of the pipeline drugs for pharmacological cardioversion benchmarked against the SOC
Figure 5: 8MM, diagnosed prevalence of AF (%), men and women, ages =40 years, 2022
Figure 6: 8MM, sources used and not used to forecast the diagnosed prevalent cases of AF
Figure 7: 8MM, sources used to forecast the diagnosed prevalent cases of AF by temporal pattern of arrhythmia
Figure 8: 8MM, sources used to forecast the diagnosed prevalent cases of AF by CHADS2 stroke risk score
Figure 9: 8MM, sources used to forecast the diagnosed prevalent cases of AF by CHA2DS2 - VASc score in men
Figure 10: 8MM, sources used to forecast the diagnosed prevalent cases of AF by CHA2DS2 - VASc score in women
Figure 11: 8MM, sources used to forecast the diagnosed prevalent cases of AF with/without moderate-to-severe mitral stenosis and/or an artificial (mechanical) heart valve
Figure 12: 8MM, sources used to forecast the diagnosed prevalent cases of AF with CKD
Figure 13: 8MM, sources used to forecast the diagnosed prevalent cases of AF with major bleeding risk by HAS-BLED score
Figure 14: 8MM, sources used to forecast the diagnosed prevalent cases of AF admitted to the ED
Figure 15: 8MM, sources used to forecast the diagnosis rate of AF
Figure 16: 8MM, total prevalent cases of AF, N, both sexes, ages =40 years, 2022
Figure 17: 8MM, diagnosed prevalent cases of AF, N, both sexes, ages =40 years, 2022
Figure 18: 8MM, diagnosed prevalent cases of AF by age, N, both sexes, 2022
Figure 19: 8MM, diagnosed prevalent cases of AF by sex, N, ages =40 years, 2022
Figure 20: 8MM, diagnosed prevalent cases of AF by temporal pattern of arrhythmia, N, both sexes, ages =40 years, 2022
Figure 21: 8MM, diagnosed prevalent cases of AF by CHADS2 stroke risk score, N, both sexes, ages =40 years, 2022
Figure 22: 8MM, diagnosed prevalent cases of AF by CHA2DS2 - VASc stroke risk score in men, N, men, ages =40 years, 2022
Figure 23: 8MM, diagnosed prevalent cases of AF by CHA2DS2 - VASc stroke risk score in women, N, women, ages =40 years, 2022
Figure 24: 8MM, diagnosed prevalent cases of AF with and without moderate-to-severe mitral stenosis and/or an artificial (mechanical) heart valve, N, both sexes, =40 years, 2022
Figure 25: 8MM, diagnosed prevalent cases of AF with CKD by stage, N, both sexes, ages =40 years, 2022
Figure 26: 8MM, diagnosed prevalent cases of AF by HAS-BLED score, N, both sexes, ages =40 years, 2022
Figure 27: 8MM, diagnosed prevalent cases of AF admitted to ED, N, both sexes, ages =40 years, 2022
Figure 28: General treatment algorithm for stroke prevention in AF
Figure 29: CCS guideline recommendations for choosing an anticoagulant
Figure 30: General treatment algorithm for long-term ventricular rate control in AF patients
Figure 31: Treatment algorithm for the maintenance of sinus rhythm in AF patients
Figure 32: Unmet needs and opportunities in AF
Figure 33: Overview of the development pipeline in atrial fibrillation
Figure 34: Key late-stage trials for the promising pipeline agents that the publisher expects to be licensed for atrial fibrillation in the 8MM during the forecast period
Figure 35: Competitive assessment of the marketed and pipeline drugs for anticoagulation benchmarked against the SOC
Figure 36: Competitive assessment of the marketed and pipeline drugs for pharmacological cardioversion benchmarked against the SOC
Figure 37: Analysis of the company portfolio gap in AF during the forecast period
Figure 38: Global (8MM) sales forecast by country for atrial fibrillation in 2022 and 2032
Figure 39: Sales forecast by class for atrial fibrillation in the US in 2022 and 2032
Figure 40: Sales forecast by class for atrial fibrillation in the 5EU in 2022 and 2032
Figure 41: Sales forecast by class for atrial fibrillation in Japan in 2022 and 2032
Figure 42: Sales forecast by class for atrial fibrillation in Canada in 2022 and 2032

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Bayer
  • Johnson and Johnson
  • Bristol Myers-Squibb
  • Daiichi Sankyo
  • Pfizer
  • Anthos Therapeutics
  • Cadrenal Therapeutics
  • Boehringer Ingelheim
  • InCarda Therapeutics

Related Topics

Related Products

Crohn's Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032 - Product Image

Crohn's Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032

  • Report
  • 116 Pages
  • Global
From
Alzheimer's Disease Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2030 - Product Image

Alzheimer's Disease Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2030

  • Drug Pipelines
  • 151 Pages
  • Global
From
Global Care Management Solutions Market by Deployment (Cloud-Based, On-Premise), Application (Case Management, Disease Management, Utilization Management), End User - Forecast 2024-2030 - Product Image

Global Care Management Solutions Market by Deployment (Cloud-Based, On-Premise), Application (Case Management, Disease Management, Utilization Management), End User - Forecast 2024-2030

  • Report
  • 182 Pages
  • Global
From
Global Chronic Disease Management Market Report and Forecast 2024-2032 - Product Image

Global Chronic Disease Management Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Advances in Mitochondrial Disease Management - Product Image

Advances in Mitochondrial Disease Management

  • Report
  • 72 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.